In 2021, Kidney Disease: Improving Global Outcomes (KDIGO) published the updated guidelines concerning the management of glomerular diseases. Herein, we have briefly discussed several key points in regard to the management of the three most common glomerular diseases in adults. Next, we have reviewed the clinical benefits, considering both renal and cardiovascular perspectives, which were observed in Type 2 diabetics with chronic kidney disease (CKD), randomized to either finerenone or placebo. Based on these encouraging data, we can assume that this molecule will soon belong to the armamentarium deemed able to delay CKD progression in Type 2 diabetics. Lastly, we have discussed the results of a recent trial showing that chlorthalidone, a thiazide diuretic, proves to be still effective in Stage 4 CKD and this, in contrast to the prevalent dogma.
Key Words
Avacopan, chronic kidney disease, finerenone, glomerular disease, KDIGO, thiazide diuretic